



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



Publication number: **0 430 336 B1**

12

## EUROPEAN PATENT SPECIFICATION

45 Date of publication of patent specification: 15.02.95 51 Int. Cl.<sup>6</sup>: C07F 9/12

21 Application number: 90203034.5

22 Date of filing: 15.11.90

54 Process for the preparation of 4-O-phosphates of dopamine and dopamine derivatives.

30 Priority: 22.11.89 IT 2248689

43 Date of publication of application:  
05.06.91 Bulletin 91/23

49 Publication of the grant of the patent:  
15.02.95 Bulletin 95/07

84 Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

56 References cited:  
EP-A- 0 167 204

73 Proprietor: ZAMBON GROUP S.p.A.  
Via della Chimica, 9  
I-36100 Vicenza (IT)

72 Inventor: Casagrande, Cesare  
Via Campogallo, 21/67  
I-20020 Arese (Milano) (IT)  
Inventor: Santangelo, Francesco  
Via Don Gnocchi, 33  
I-20148 Milano (IT)

74 Representative: Marchi, Massimo et al  
c/o Marchi & Mittler s.r.l.  
Viale Lombardia 20  
I-20131 Milano (IT)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).


## Description

The present invention relates to a process for the preparation of monophosphates and particularly it relates to a process for the preparation of 4-O-phosphates of dopamine and dopamine derivatives.

5 The European patent No. 0 167 204 (SIMES Società Italiana Medicinali e Sintetici S.p.A.) describes a method for improving the absorption and the effectiveness of catecholamines consisting in the monophosphorylation of one of the catecholic hydroxyl groups.

However, the monophosphorylation processes therein described require the use of intermediates which are selectively protected on the catecholic function or a separation by chromatography or crystallization  
10 from mixtures containing both 3-O-phosphate and 4-O-phosphate.

We have now found that mixtures containing both 3-O-phosphate and 4-O-phosphate of dopamine or dopamine derivatives of formula



wherein


R is a hydrogen atom, a C<sub>1</sub>-C<sub>6</sub> alkyl, a C<sub>1</sub>-C<sub>6</sub> phenylalkyl optionally substituted by alkoxy groups, alkyl groups or halogen atoms, or an acyl of a natural aminoacid; and  
25

R<sub>1</sub> is a hydrogen atom, a C<sub>1</sub>-C<sub>6</sub> alkyl or a C<sub>1</sub>-C<sub>6</sub> phenylalkyl optionally substituted by alkoxy groups, alkyl groups or halogen atoms;

are converted into the only 4-O-phosphate isomer which is readily isolated as the sole product from the reaction mixture in high yield and high purity, by treatment with a strong mineral acid.

30 Therefore, this invention relates to a process for the preparation of 4-O-phosphates of dopamine and dopamine derivatives comprising

(i) the monophosphorylation of a compound of formula




wherein


45 R is a hydrogen atom, a C<sub>1</sub>-C<sub>6</sub> alkyl, a C<sub>1</sub>-C<sub>6</sub> phenylalkyl optionally substituted by alkoxy groups, alkyl groups or halogen atoms, or an acyl of a natural aminoacid; and

R<sub>1</sub> is a hydrogen atom, a C<sub>1</sub>-C<sub>6</sub> alkyl or a C<sub>1</sub>-C<sub>6</sub> phenylalkyl optionally substituted by alkoxy groups, alkyl groups or halogen atoms;

(ii) the isomerization of the so obtained 3-O-phosphate and 4-O-phosphate mixture by treatment with a  
50 strong mineral acid to yield a compound of formula



10  
 wherein R and R<sub>1</sub> have the above reported meanings; and  
 (iii) the optional esterification of the compound of formula II to give a compound of formula



25  
 wherein

R and R<sub>1</sub>  
 R<sub>2</sub>

have the above mentioned meanings; and  
 is a phenylalkyl having 1 to 3 carbon atoms in the alkyl moiety or a C<sub>1</sub>-C<sub>6</sub> alkyl  
 optionally substituted by hydroxyl, alkoxy, acyloxy, amino, carboxy or alkoxycarbonyl  
 groups.

The process of the present invention is shown in the following scheme.

Scheme 1

5

10

15


20

25

30

35

40



wherein

- 45 R and R<sub>1</sub> have the above mentioned meanings; and  
 R<sub>2</sub> is a phenylalkyl having from 1 to 3 carbon atoms in the alkyl moiety or a C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by hydroxyl, alkoxy, acyloxy, amino, carboxy or alkoxycarbonyl groups.

The compounds of formula II and III are described in the above cited European Patent.

50 The dopamine derivative of formula I is monophosphorylated according to conventional methods with, for example, phosphorylating agents such as orthophosphoric acid, pyrophosphoric acid, phosphorus pentoxide, polyphosphoric acid, chlorophosphoric acid, phosphorus oxychloride and phosphorus oxybromide.

The mixture of 3-O-phosphate and 4-O-phosphate isomers is dissolved in a strong mineral acid and the 4-O-phosphate isomer of formula II separates by cooling as the only product.

55 Then, the so obtained compound of formula II is optionally esterified to achieve the phosphoric diesters of formula III.

Alternatively, the compounds of formula II or III, wherein one of R and R<sub>1</sub> is different from hydrogen, can be prepared from the corresponding compounds of formula II or III wherein at least one of R and R<sub>1</sub> is

a hydrogen atom, by acylation or alkylation of the amino group.

The acylation reaction is carried out by treatment with suitably protected natural aminoacids and is then followed by the optional deprotection to give the compounds of formula II or III wherein R is an acyl of a natural aminoacid.

5 The alkylation can be carried out by reaction with alkyl or phenylalkyl halides or with esters of alkyl or arylsulfonic acids, or, alternatively, by condensation with aldehydes or ketones and subsequent reduction with hydrides or by hydrogenation.

The compounds of formula II or III wherein at least one of R or R<sub>1</sub> is a C<sub>1</sub>-C<sub>6</sub> alkyl or a C<sub>1</sub>-C<sub>6</sub> phenylalkyl optionally substituted by alkoxy groups, alkyl groups or halogen atoms are so obtained.

10 Specific examples of compounds which can be prepared according to the process of this invention are:

dopamine 4-O-dihydrogenphosphate

N-methyldopamine 4-O-ethylhydrogenphosphate

dopamine 4-O-dihydrogenphosphate hydrochloride

N-methyldopamine 4-O-dihydrogenphosphate

15 N-methyldopamine 4-O-dihydrogenphosphate hydrochloride

N-(L-gamma-glutamyl)dopamine 4-O-dihydrogenphosphate

N-(L-gamma-glutamyl)dopamine 4-O-ethylhydrogenphosphate

bis[N-(L-gamma-glutamyl)dopamine 4-O-ethylhydrogenphosphate] calcium salt

N-(L-gamma-glutamyl)dopamine 4-O-(3-pivaloyloxypropyl)hydrogenphosphate

20 bis[N-(L-gamma-glutamyl)dopamine 4-O-(3-pivaloyloxypropyl)hydrogenphosphate]calcium salt

N,N-di-n-propyldopamine 4-O-dihydrogenphosphate

dopamine 4-O-ethylhydrogenphosphate

N-ethyldopamine 4-O-dihydrogenphosphate


N-ethyldopamine 4-O-dihydrogenphosphate hydrochloride

25 dopamine 4-O-(3-pivaloyloxypropyl)hydrogenphosphate

N-glycyl-dopamine 4-O-dihydrogenphosphate

The treatment of the mixture of phosphorylated products, obtained starting from the dopamine derivative of formula I, with a strong mineral acid results in the isomerization reaction shown in the following scheme

Scheme 2



45 wherein

R and R<sub>1</sub> have the above mentioned meanings;

and in the contemporaneous crystallization of the monophosphate of formula II in the form of the salt of said mineral acid.

50 The isomerization reaction, which is a further object of the present invention, is carried out by dissolving the mixture of both the 3-O-phosphate of formula IV and the 4-O-phosphate of formula II, in a strong mineral acid optionally in the presence of a solvent.

The reaction can also be carried out directly in the same phosphorylation reaction medium after decomposition, according to usual methods, of the excess of the phosphorylating agent, if any.

55 Examples of strong mineral acids are hydrochloric acid, hydrobromic acid and sulfuric acid.

Concentrate hydrochloric acid is preferably used.

Suitable solvents are lower alcohols such as, for example, methanol, ethers such as, for example, diethylene glycol, dimethyl ether, ethyl ether and dioxane, ketones such as, for example, acetone or

mixtures of water and a watermiscible organic solvent.

The 4-O-phosphate of formula II separates from the reaction medium in the form of the salt of the used acid by mere cooling of the acid solution, generally at a temperature of from 0 to 10°C.

An important feature of this invention is that, the isomerization of compound IV is almost complete and results in the 4-O-phosphate isomer in a very high yield, irrespective of the ratio of 3-O-phosphate of formula IV to 4-O-phosphate of formula II in the starting mixture.

Furthermore, the unreacted dopamine derivative I still present in the phosphorylation mixture, if any, is concentrated in the crystallization liquors from which it can be easily recovered to be phosphorylated again.

As shown in Scheme 1, the 4-O-phosphate of formula II can be esterified to the phosphoric diesters of formula III.

This esterification reaction can be carried out according to several conventional methods.

However, we have found, and this is a further object of the present invention, that the esterification reaction may be advantageously carried out by treating a solution of a compound of formula II, with a compound of formula



wherein

$R_2$  has the above mentioned meanings, and

X is a leaving group such as halogen, preferably iodine, or an alkyl or arylsulfonyloxy group, preferably a methylsulfonyloxy group,

in a suitable aprotic organic solvent and in the presence of a tetraalkylammonium hydroxide.

This esterification reaction is preferably carried out by using tetramethylammonium hydroxide in an aprotic organic solvent selected from acetonitrile and toluene.

As far as we know this esterification reaction of monophosphate compounds has never been described for the selective preparation of 4-O-phosphate diesters of catecholamine-like compounds.

The selectivity of this esterification reaction for preparing 4-O-phosphate diesters of catecholamines is noticeable.

In fact, the phosphoric diester of formula III is obtained in high yields and, above all, selectively and highly pure.

Neither isomerization by-products nor phosphoric triesters are present in the esterification mixture.

This selectivity in the esterification reaction is even more surprising in view of the fact that significant amounts of by-products due to undesired isomerization were found when the reaction was carried out according to conventional methods, such as with alcohols in the presence of N,N-dicyclohexylcarbodiimide or after having activated the phosphate as chloride (by treatment, for example, with thionyl chloride).

Also when the esterification is carried out in the presence of bases different from tetraalkylammonium hydroxide, such as alkaline or alkaline-earth hydroxides, carbonates or bicarbonates, the phosphoric diesters III is obtained in low yields and mixed to several by-products which hinder purification.

It will be evident to the man skilled in the art that protection of the amino group of the compound of formula II can be convenient before carrying out the esterification reaction.

The protection reaction performed with protecting agents known in organic chemistry such as the halides of carbonic acid derivatives.

Preferred protecting groups are benzyloxycarbonyl and t.butoxycarbonyl.

At the end of the esterification reaction the protecting group, if any, is removed according to conventional techniques such as, for example, catalytic hydrogenation, to yield the compound of formula III.

Alternatively, as already mentioned, the compounds of formula II and III wherein one of R and  $R_1$  is different from hydrogen can be prepared from the corresponding compounds of formula II or III wherein at least one of R and  $R_1$  is a hydrogen atom.

Also in this case it can be convenient to make use of suitable protecting groups according to conventional techniques.

In order to better illustrate the present invention without limiting it, the following examples are now given.

## Example 1

Preparation of N-methyldopamine 4-O-dihydrogenphosphate hydrochloride

## 5 Method A

Into a ten-liter flask containing phosphorus pentoxide (781.5 g; 5.5 moles), 85% phosphoric acid (392.8 ml; 5.775 moles;  $d = 1.695$ ) was added dropwise, under vigorous stirring and nitrogen flow, keeping the temperature at about 150 °C.

10 At the end of the addition, the suspension was kept at 150 °C up to complete dissolution.

The so obtained thick clear solution was cooled to 40 °C and then N-methyldopamine hydrochloride (800 g; 3.931 moles) was added.

The mixture was heated to 150 °C in 30 minutes, cooled to 60 °C and quickly diluted with water (2.4 l).

15 After further 30 minutes at 80 °C, the solution was further diluted with water up to a finale volume of 12 l.

HPLC analysis [anionic exchange column, Spherisorb SAX 5 micron (Phase separation), mobile phase 0.02 M  $\text{NH}_4\text{H}_2\text{PO}_4$ ] showed that the mixture contained N-methyldopamine (11%), N-methyldopamine 3-O-dihydrogenphosphate (29%) and N-methyldopamine 4-O-dihydrogenphosphate (31%).

The solution was applied on a strongly acid exchange resin Dowex M 15 column.

20 After washing of the column with water (16 l), the product was eluted with 1N HCl (50 l) which was collected and concentrated to small volume.

The residue was taken up with absolute ethanol (2 l) obtaining a first precipitation of compound (478 g).

The mother liquors were evaporated and the residue was taken up with ethanol (0.5 l) obtaining a further precipitation (110 g); by repeating the procedure a third crop of compound (30.5 g) was obtained.

25 The three precipitates were combined obtaining a total amount of 618.5 g (55.5% yield) of N-methyldopamine 4-O-dihydrogenphosphate hydrochloride.

## Method B

30 The phosphorylation reaction was repeated according to the procedure described for method A starting from 80 g (0.393 moles) of N-methyldopamine hydrochloride.

The reaction mixture was directly diluted with concentrated HCl (400 ml), keeping under stirring for 4 hours, and it was cooled at 5-10 °C for 48 hours.

35 The precipitate was filtered, suspended in acetone under stirring, filtered again and dried under vacuum obtaining N-methyldopamine 4-O-dihydrogenphosphate hydrochloride (56.3 g; 50% yield).

The phosphorylation reaction was repeated according to the procedure described for method A starting from N-methyldopamine as free base, obtaining N-methyldopamine 4-O-dihydrogenphosphate hydrochloride substantially with the same yields.

## 40 Example 2

Preparation of N-methyldopamine 4-O-dihydrogenphosphate

45 Into a flask containing water (2.7 l) under nitrogen flow, a 40% sodium hydroxide solution (420 ml) and N-methyldopamine 4-O-dihydrogenphosphate hydrochloride (1.196 kg; 4.216 moles), prepared as described in example 1, were added contemporaneously while the temperature was kept at from 15 to 20 °C and the pH of the suspension at from 3 to 5.

At the end of the addition (final pH about 4) and after vigorous stirring for further 30 minutes, the suspension was filtered.

50 The solid was washed with water, with ethanol and dried under vacuum obtaining N-methyldopamine 4-O-dihydrogenphosphate (1.005 kg; 96% yield).

m.p. 207-209 °C

$^1\text{H-NMR}$  (300 MHz,  $\text{D}_2\text{O}$ ):  $\delta$  (ppm): 2.75 (3H, s); 3.00 (2H, t); 3.47 (2H, t); 6.88 (1H, dd); 6.95 (1H, d); 7.29 (1H, d).

55

## Example 3

Preparation of dopamine 4-O-dihydrogenphosphate hydrochloride

5 A mixture of dopamine 3-O-dihydrogenphosphate and dopamine 4-O-dihydrogenphosphate in ratio 1:1 (123.6 g; 0.530 moles) was dissolved in concentrate HCl (300 ml) and cooled at 5-10 °C for 48 hours.

The precipitate was filtered, suspended in acetone, kept under stirring for 30 minutes, filtered again and dried under vacuum.

Dopamine 4-O-dihydrogenphosphate hydrochloride (56 g) was obtained.

10 Further product (36 g) was obtained by evaporation to dryness of acetone and mother liquors, dissolution of the obtained residue in concentrated HCl (200 ml), cooling the thus obtained solution and filtration of the solid which separates by cooling.

As a total amount, 92 g of dopamine 4-O-dihydrogenphosphate hydrochloride (64% yield) was obtained, m.p. 147-150 °C. <sup>1</sup>H-NMR (300 MHz, D<sub>2</sub>O): delta (ppm): 2.90 (2H, t); 3.25 (2H, t); 6.63 (1H, dd); 6.90 (1H, d); 7.22 (1H, dd).

By working in a similar way the following compounds were obtained.

N-ethyldopamine 4-O-dihydrogenphosphate hydrochloride

20 m.p. 150 °C (dec.)

<sup>1</sup>H-NMR (300 MHz, D<sub>2</sub>O): delta (ppm): 1.27 (3H, t); 2.94 (2H, t); 3.08 (2H, q); 3.28 (2H, t); 6.82 (1H, dd); 6.90 (1H, d); 7.23 (1H, dd).

N,N-di-n-propyldopamine 4-O-dihydrogenphosphate hydrochloride

25

m.p. 181-186 °C (inner salt)

<sup>1</sup>H-NMR (300 MHz, D<sub>2</sub>O): delta (ppm): 0.97 (6H, t); 1.65-1.78 (4H, m); 2.99 (2H, t); 3.11-3.16 (4H, m); 3.48 (2H, m); 6.83 (1H, dd); 6.90 (1H, d).

## 30 Example 4

Preparation of N-benzyloxycarbonyldopamine 4-O-dihydrogenphosphate

To a mixture of dopamine 4-O-dihydrogenphosphate hydrochloride (80 g; 0.295 moles), prepared as described in example 3, in 2N NaOH (594 ml; 1.188 moles), a 50% solution of benzyl chlorocarbonate in toluene (0.297 moles) and a 2N solution of NaOH (163 ml; 0.327 moles) were added dropwise contemporaneously at a temperature of from 5 to 10 °C.

After 3 hours at 5 °C, the reaction mixture was acidified up to pH 1.5 with 3N HCl.

The precipitate was filtered, taken up with ethyl ether, triturated and filtered again.

40 N-benzyloxycarbonyldopamine 4-O-dihydrogenphosphate sodium salt was obtained (97 g; 84% yield, m.p. 189-191 °C) and suspended in ethyl acetate (900 ml).

0.3N HCl (829 ml) was added to the suspension.

The mixture was kept under stirring till complete dissolution and the organic phase was then separated.

The aqueous phase was again extracted twice with ethyl acetate.

45 The combined extracts were evaporated to dryness under vacuum at a temperature lower than 30 °C.

The residue was taken up with methylene chloride obtaining N-benzyloxycarbonyldopamine 4-O-dihydrogenphosphate (79 g; 86% yield; m.p. 132-134 °C).

<sup>1</sup>H-NMR (300 MHz, D<sub>2</sub>O): delta (ppm): 2.70 (2H, t); 3.36 (2H, t); 5.05 (2H, s); 6.73 (1H, dd); 6.83 (1H, d); 7.16 (1H, dd); 7.30-7.48 (5H, m).

50

## Example 5

Preparation of N-benzyloxycarbonyldopamine 4-O-ethylhydrogenphosphate ammonium salt

55 To a suspension of N-benzyloxycarbonyldopamine 4-O-dihydrogenphosphate (40 g; 0.1009 moles), prepared as described in example 4, in ethanol (400 ml), a 20% solution of tetramethylammonium hydroxide in methanol (0.218 moles) was added.



After complete dissolution, the solution was evaporated to dryness, the residue was taken up with acetonitrile (800 ml) and ethyl iodide (34 g; 0.218 moles) was added.

After three hours, the precipitate was filtered and the solution was evaporated to dryness under vacuum.

The obtained residue was taken up with 0.1N HCl (1.09 l) and extracted with ethyl acetate.

5 The organic phase was washed with a NaCl saturate solution (150 ml), basified with ammonia (10 ml) and evaporated to dryness.

The residue was taken up with methylene chloride and N-benzyloxycarbonyldopamine 4-O-ethylhydrogenphosphate ammonium salt (42 g; 93% yield) was obtained, as a pure oil by thin layer chromatography (eluent CH<sub>3</sub>COH:H<sub>2</sub>O:toluene:acetone:n.butanol = 1:1:1:1:1, detection I<sub>2</sub> vapours).

10 <sup>1</sup>H-NMR (300 MHz, D<sub>2</sub>O): delta (ppm): 1.25 (3H, t); 2.72 (2H, t); 3.37 (2H, t); 4.03 (2H, q); 5.06 (2H, s); 6.76 (1H, dd); 6.85 (1H, d); 7.18 (1H, dd); 7.32-7.49 (5H, m).

By working in a similar way, the following compound was obtained:

N-benzyloxycarbonyldopamine 4-O-(3-pivaloyloxypropyl)hydrogenphosphate ammonium salt

15 <sup>1</sup>H-NMR (300 MHz, D<sub>2</sub>O): delta (ppm): 1.00 (9H, s); 1.83 (2H, quintet); 2.61 (2H, t); 3.26 (2H, t); 3.93-4.02 (4H, m); 4.93 (2H, s); 6.58 (1H, dd); 6.78 (1H, d); 7.10 (2H, d); 7.15-7.25 (5H, m).

#### Example 6

20 Preparation of dopamine 4-O-ethylhydrogenphosphate

A mixture of N-benzyloxycarbonyl dopamine 4-O-ethylhydrogenphosphate ammonium salt (42 g; 0.101 moles), prepared as described in example 5, and 10% palladium on activated charcoal (10 g) in 95% ethanol (800 ml) was hydrogenated.

25 At the end of hydrogen absorption, the catalyst was filtered and the solution was concentrated to a volume of about 80 ml.

Dopamine 4-O-ethylhydrogenphosphate (16.7 g; 63% yield) separated.

m.p. 180-182 °C.

30 <sup>1</sup>H-NMR (300 MHz, D<sub>2</sub>O): delta (ppm): 1.28 (3H, t); 2.95 (2H, t); 3.28 (2H, t); 4.08 (2H, q); 6.84 (1H, dd); 6.93 (1H, d); 7.25 (1H, dd).

By working in a similar way, the following compound was obtained:

Dopamine 4-O-(3-pivaloyloxypropyl)hydrogenphosphate

35 m.p. 203-205 °C

<sup>1</sup>H-NMR (300 MHz, D<sub>2</sub>O): delta (ppm): 1.12 (9H, s); 1.99 (2H, q); 2.93 (2H, t); 3.27 (2H, t); 4.05-4.12 (4H, m); 6.82 (2H, dd); 6.90 (2H, d); 7.23 (2H, d).

#### 40 Example 7

Preparation of N-(L-gamma-glutamyl)dopamine 4-O-dihydrogenphosphate

45 To a suspension of dopamine 4-O-dihydrogenphosphate hydrochloride (161 g; 0.6 moles), prepared as described in example 3, and sodium bicarbonate (151.6 g; 1.8 moles) in water (2 l), N-benzyloxycarbonyl-L-glutamic acid alpha-benzyl-gamma-(N-succinimido)diester (309 g; 0.66 moles) and absolute ethanol (1 l) were added.

The reaction mixture was warmed to 50-55 °C and the dissolution was complete after an hour.

50 After further two hours a part of the solvent (about 1 l) was evaporated and the solution was then washed with ethyl acetate, acidified with concentrate HCl and extracted with ethyl acetate.

The combined organic extracts were washed with a 15% NaCl aqueous solution (3 x 400 ml), dried on sodium sulfate, filtered, basified with ammonia, diluted with ethanol and, at last, evaporated to dryness.

A residue (N-benzyloxycarbonyl-L-glutamyl-gamma-benzyl ester dopamine 4-O-dihydrogenphosphate ammonium salt) was obtained and used in the next step without further purification.

55 The crude was dissolved in water (1.5 l), diluted with ethanol (1.5 l) and 10% palladium on activated charcoal (72 g; 50% H<sub>2</sub>O) was then added.

The suspension was hydrogenated under an initial pressure of 20-25 atmospheres and at a temperature of 25-30 °C.

After 5 hours, at the end of hydrogen absorption, the catalyst was filtered and the solution was evaporated to a volume of 600 ml.

The so obtained solution was acidified with concentrate HCl (75 ml), charcoal was added and the suspension was filtered washing with water up to a total volume of 850 ml.

5 The solution was further diluted with absolute ethanol (1.8 l) and seeded with some crystals of product (0.5 g).

The compound precipitated very quickly and after 2 hours it was filtered, washed first with 70% ethanol (250 ml) and then with ethanol (500 ml).

10 After drying at 50 °C under vacuum overnight, N-(L-gamma-glutamyl-dopamine) 4-O-dihydrogen-phosphate (105 g; 58% yield) was obtained.

<sup>1</sup>H-NMR (300 MHz, D<sub>2</sub>O): delta (ppm): 2.08 (2H, q); 2.39 (2H, t); 2.76 (2H, t); 3.39-3.57 (2H, m); 4.79 (1H, t), 6.78 (1H, dd); 6.85 (1H, d); 7.18 (1H, dd).

By working in a similar way, the following compounds were obtained:

15 bis[N-(L-gamma-glutamyl-dopamine) 4-O-ethylhydrogenphosphate] calcium salt

<sup>1</sup>H-NMR (300 MHz, D<sub>2</sub>O): delta (ppm): 1.28 (3H, t); 2.01-2.08 (2H, m); 2.32-2.38 (2H, m); 3.76 (2H, t); 3.45 (2H, t); 3.68 (1H, t); 4.06 (2H, q); 6.79 (1H, dd); 6.87 (1H, d); 7.20 (1H, dd).

20 bis[N-(L-gamma-glutamyl-dopamine) 4-O-(3-pivaloyloxypropyl)-hydrogenphosphate] calcium salt

<sup>1</sup>H-NMR (300 MHz, D<sub>2</sub>O): delta (ppm): 1.13 (9H, s); 1.95-2.18 (4H, m); 2.32-2.38 (2H, m); 2.76 (2H, t); 3.45 (2H, t); 3.67-3.72 (2H, m); 4.04-4.15 (4H, m); 6.78 (1H, dd); 6.86 (1H, d); 7.18 (1H, d).

25 N-glycyl-dopamine 4-O-dihydrogenphosphate


<sup>1</sup>H-NMR (300 MHz, D<sub>2</sub>O): delta (ppm): 2.76 (2H, t); 3.48 (2H, t); 3.70 (2H, s); 6.78 (1H, dd); 6.84 (1H, d); 7.17 (1H, dd).

### 30 Claims

1. A process for the preparation of 4-O-phosphates of dopamine and dopamine derivatives comprising (i) the monophosphorylation of a compound of formula

35

40




( I )

wherein

- 45 **R** is a hydrogen atom, a C<sub>1</sub>-C<sub>5</sub> alkyl, a C<sub>1</sub>-C<sub>6</sub> phenylalkyl optionally substituted by alkoxy groups, alkyl groups or halogen atoms, or an acyl of a natural aminoacid; and
- R<sub>1</sub>** is a hydrogen atom, a C<sub>1</sub>-C<sub>6</sub> alkyl or a C<sub>1</sub>-C<sub>6</sub> phenylalkyl optionally substituted by alkoxy groups, alkyl groups or halogen atoms;

- 50 (ii) the isomerization of the so obtained 3-O-phosphate and 4-O-phosphate mixture by treatment with a strong mineral acid to yield a compound of formula


55



10 wherein

R and R<sub>1</sub> have the above reported meanings; and

(iii) the optional esterification of the compound of formula II to give a compound of formula



20 wherein

R and R<sub>1</sub> have the above mentioned meanings; and

R<sub>2</sub> is a phenylalkyl having 1 to 3 carbon atoms in the alkyl moiety or a C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by hydroxyl, alkoxy, acyloxy, amino, carboxy or alkoxy-carbonyl groups.

- 25
2. A process according to claim 1, wherein the isomerization step is performed with a strong mineral acid selected from hydrochloric acid, hydrobromic acid and sulfuric acid optionally in the presence of a solvent.

- 35
3. A process according to claim 1, wherein the esterification step is carried out by treating a solution of a compound of formula II with a compound of formula



wherein

R<sub>2</sub> has the meanings mentioned in claim 1; and

X is a leaving group selected from halogen, alkyl- and arylsulfonyloxy;


in a suitable aprotic organic solvent and in the presence of a tetraalkylammonium hydroxide.

- 45
4. A process according to claim 3 wherein the tetraalkylammonium hydroxide is tetramethylammonium hydroxide.

# Patentansprüche

- 50
1. Verfahren zur Herstellung von 4-O-Phosphaten von Dopamin und Dopaminderivaten, umfassend

(i) die Monophosphorylierung einer Verbindung der Formel




worin

R ein Wasserstoffatom, eine C<sub>1</sub>-C<sub>6</sub>-Alkylgruppe, eine C<sub>1</sub>-C<sub>6</sub>-Phenylalkylgruppe, die gegebenenfalls durch Alkoxygruppen, Alkylgruppen oder Halogenatome substituiert ist, oder einen Acylrest einer natürlichen Aminosäure bedeutet; und

R<sub>1</sub> ein Wasserstoffatom, eine C<sub>1</sub>-C<sub>5</sub>-Alkylgruppe oder eine C<sub>1</sub>-C<sub>6</sub>-Phenylalkylgruppe, die gegebenenfalls durch Alkoxygruppen, Alkylgruppen oder Halogenatome substituiert ist, bedeutet;

ii) die Isomerisierung des so erhaltenen Gemisches aus 3-O-Phosphat und 4-O-Phosphat durch Behandlung mit einer starken Mineralsäure zu einer Verbindung der Formel




worin

R und R<sub>1</sub> die oben angegebenen Bedeutungen besitzen;

und

iii) gegebenenfalls die Veresterung der Verbindung der Formel II zu einer Verbindung der Formel




worin

R und R<sub>1</sub> die oben angegebenen Bedeutungen besitzen; und  
R<sub>2</sub> für Phenylalkyl mit 1 bis 3 Kohlenstoffatomen in der Alkyleinheit oder C<sub>1</sub>-C<sub>6</sub>-Alkyl, das gegebenenfalls durch Hydroxy-, Alkoxy-, Acyloxy-, Amino-, Carboxy- oder Alkoxycarbonylgruppen substituiert ist, steht.

55 2. Verfahren nach Anspruch 1, wobei die Isomerisierungsstufe mit einer starken Mineralsäure, die ausgewählt ist unter Chlorwasserstoffsäure, Bromwasserstoffsäure und Schwefelsäure, gegebenenfalls in Anwesenheit eines Lösungsmittels durchgeführt wird.

3. Verfahren nach Anspruch 1, wobei die Veresterungsstufe durch Behandlung einer Lösung einer Verbindung der Formel II mit einer Verbindung der Formel



worin


$R_2$  die in Anspruch 1 angegebenen Bedeutungen besitzt; und

X eine Abgangsgruppe, ausgewählt unter Halogen, Alkyl- und Arylsulfonyloxy, bedeutet, in einem geeigneten aprotischen organischen Lösungsmittel und in Anwesenheit eines Tetraalkylammoniumhydroxids durchgeführt wird.

4. Verfahren nach Anspruch 3, wobei es sich bei dem Tetraalkylammoniumhydroxid um Tetramethylammoniumhydroxid handelt.

# Revendications

1. Procédé de préparation de 4-O-phosphates de dopamine et de dérivés de dopamine qui comprend :  
(i) la monophosphorylation d'un composé de formule :




dans laquelle

R est un atome d'hydrogène, un alkyle  $C_1-C_6$ , un phénylalkyle  $C_1-C_6$  éventuellement substitué par des groupes alcoxy, des groupes alkyles ou des atomes d'halogène, ou un acyle provenant d'un acide naturel ; et

$R_1$  est un atome d'hydrogène, un alkyle  $C_1-C_6$  ou un phénylalkyle  $C_1-C_6$  éventuellement substitué par des groupes alcoxy, des groupes alkyles, ou des atomes d'halogène ;


(ii) l'isomérisation du mélange de 3-O-phosphate et 4-O-phosphate ainsi obtenu par traitement avec un acide minéral fort pour donner un composé de formule :



dans laquelle

R et  $R_1$  ont les significations indiquées ci-dessus ; et

(iii) l'estérification éventuelle du composé de formule II pour donner un composé de formule :



dans laquelle

R et R<sub>1</sub> ont les significations indiquées ci-dessus ; et

15 R<sub>2</sub> est un phénylalkyle ayant de 1 à 3 atomes de carbone dans le radical alkyle ou un alkyle C<sub>1</sub>-C<sub>6</sub> éventuellement substitué par des groupes hydroxyle, alcoxy, acyloxy, amino, carboxy ou alcoycarbonyle.

- 20 2. Procédé selon la revendication 1; dans lequel on réalise l'étape d'isomérisation avec un acide minéral fort choisi parmi les acide chlorhydrique, acide bromhydrique et acide sulfurique éventuellement en présence d'un solvant.
3. Procédé selon la revendication 1, dans lequel on réalise l'étape d'estérification en traitant une solution d'un composé de formule II avec un composé de formule :



dans laquelle

R<sub>2</sub> a les significations indiquées à la revendication 1 ; et

30 X est un groupe labile choisi parmi les halogène, alkyle- et arylsulfonyloxy; dans un solvant organique aprotique approprié et en présence d'un hydroxyde de tétraalkylammonium.

4. Procédé selon la revendication 3, dans lequel l'hydroxyde de tétraalkylammonium est l'hydroxyde de tétraméthylammonium.
- 35
- 40
- 45
- 50
- 55